HGH and Sleep: The Nocturnal Growth Hormone Pulse

Endogenous growth hormone (GH) is released from the anterior pituitary in discrete pulses rather than at a steady rate, so plasma GH rises and falls sharply around each secretory episode. Across the 24-hour cycle the single most prominent of these episodes in healthy young adults occurs shortly after sleep onset, in association with the first period of slow-wave (deep, non-REM) sleep.

Research-use-only: This page describes endogenous GH secretory physiology — the body’s own pulsatile GH release and its timing relative to sleep. It is descriptive human physiology, not a health claim. The recombinant research compound sold by RetaLABS, somatropin, is supplied for laboratory research use only; its molecular details are covered in the HGH molecular profile. Nothing here implies that any research compound improves sleep, or that sleep increases usable GH for any product purpose; the sleep–GH relationship is about the body’s own hormone.

Keeping that distinction in mind, this page summarises what the physiology literature reports about the link between sleep architecture and the timing of the endogenous GH pulse.

The observation that GH is secreted during sleep was first demonstrated in 1968 by Takahashi, Kipnis and Daughaday in the Journal of Clinical Investigation. Sampling plasma GH through the night in young adults, they reported that in 7 of 8 subjects a plasma GH peak lasting roughly 1.5–3.5 hours appeared with the onset of deep sleep.

Two further observations from that study tied the pulse to sleep itself rather than to the clock: the GH peak was delayed if sleep onset was delayed, and a fresh peak appeared when subjects returned to sleep after a forced awakening. Together these established that endogenous GH secretion is linked to deep (slow-wave) sleep. In men specifically, a substantial fraction of daily GH output — reported as approximately 70% in men — occurs during early sleep throughout adulthood.

Beyond the timing of the first pulse, the physiology literature reports a quantitative coupling between the amount of slow-wave sleep (SWS) and the amount of GH secreted. In a study of healthy men across the adult age range, the amount of GH secretion was significantly associated with slow-wave sleep (P<.001), independently of age. The broader evidence shows a consistent relationship in which more slow-wave sleep accompanies increased GH secretion, while awakenings accompany decreased GH release.

The direction of this coupling has also been probed experimentally. In normal young men, pharmacologically increasing slow-wave sleep produced a doubling of GH secretion, arising from an increase in the amplitude and duration of the first GH pulse after sleep onset, and this was correlated with the increase in deep sleep. (The experimental probe used in that study, gamma-hydroxybutyrate, is a controlled substance referenced here only for mechanistic attribution — not as a recommendation or a product-adjacent claim.)

The same two hypothalamic neuropeptides that govern GH release — Growth Hormone-Releasing Hormone (GHRH), which stimulates secretion, and somatostatin, which inhibits it — also appear to participate in sleep regulation. The sleep-onset GH pulse is described as being driven by a surge of hypothalamic GHRH release. More specifically, GH secretion at the beginning of sleep appears to be primarily regulated by GHRH stimulation occurring during a period of relative somatostatin withdrawal.

This points to a reciprocal interaction rather than a one-way link. In the neurochemical model of sleep regulation, GHRH and corticotropin-releasing hormone (CRH) play a key reciprocal role: at least in males, GHRH is a common stimulus of both non-rapid-eye-movement (NREM) sleep and GH secretion. In other words, the neuropeptide that promotes the deep-sleep GH pulse is also implicated in promoting the deep sleep itself.

Because the nocturnal GH pulse depends on slow-wave sleep continuity, fragmentation and sleep loss perturb the nocturnal somatotropic profile: awakenings are associated with decreased GH release. The direction of this effect is firmly established, though its magnitude is study- and protocol-specific and is not captured by any single figure.

Ageing illustrates the relationship over the lifespan. In healthy men, slow-wave sleep fell from 18.9% of sleep in early adulthood (16–25 years) to 3.4% in midlife (36–50 years), and this was paralleled by a major decline in GH secretion of approximately 372 µg per decade (P<.001). The early-adulthood-to-midlife decline in slow-wave sleep tracks the major decline in nocturnal GH secretion; later in life (after about 50 years) sleep fragments further and REM sleep declines as evening cortisol rises. This is descriptive physiology of how endogenous slow-wave sleep and the endogenous nocturnal GH pulse decline together with age — not a suggestion of supplementation, restoration, or correction of any kind.

Sources:

• Takahashi Y, Kipnis DM, Daughaday WH. Growth hormone secretion during sleep. J Clin Invest. 1968;47(9):2079–2090. PMID 5675428.
• Van Cauter E, Plat L, Copinschi G. Interrelations between sleep and the somatotropic axis. Sleep. 1998;21(6):553–566. PMID 9779515.
• Van Cauter E, Leproult R, Plat L. Age-related changes in slow wave sleep and REM sleep and relationship with growth hormone and cortisol levels in healthy men. JAMA. 2000;284(7):861–868. PMID 10938176.
• Van Cauter E, Plat L, Scharf MB, et al. Simultaneous stimulation of slow-wave sleep and growth hormone secretion by gamma-hydroxybutyrate in normal young men. J Clin Invest. 1997;100(3):745–753. PMID 9239423.
• Steiger A. Neurochemical regulation of sleep. J Psychiatr Res. 2007;41(7):537–552. PMID 16777143.
• Van Cauter E, Latta F, Nedeltcheva A, et al. Reciprocal interactions between the GH axis and sleep. Growth Horm IGF Res. 2004;14 Suppl A:S10–S17. PMID 15135771.

Continue across the HGH research cluster: the HGH research guide, the HGH molecular profile, how recombinant HGH compares with GH secretagogue peptides and with IGF-1, plus HGH and body composition and HGH pharmacokinetics. Research-grade vials: HGH 100IU, 240IU and 400IU kits. The GHRH-driven secretagogues are covered in the CJC-1295 and Ipamorelin guide, and laboratory handling in the reconstitution and storage guide.